Drug Type Biosimilar, Monoclonal antibody |
Synonyms NeuLara, Ustekinumab biosimilar |
Target |
Mechanism IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | Phase 1 | AU | 15 Oct 2019 | |
Autoimmune Diseases | Phase 1 | - | - |